What is the 13F Pro Quality Score for TNXP?

13F Pro ranks Tonix Pharmaceuticals Holding Corp. (TNXP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TNXP's current score at https://13fpro.ai/research/TNXP (free sign-up required for the full ranking).

Which hedge funds own the most TNXP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TNXP include BlackRock,, VANGUARD CAPITAL MANAGEMENT, CITADEL ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TNXP as soon as new 13F filings post.

Where does 13F Pro source TNXP data?

All Tonix Pharmaceuticals Holding Corp. fundamentals and ownership data come directly from SEC EDGAR. Tonix Pharmaceuticals Holding Corp. files with the SEC under CIK 1430306. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TNXP in?

Tonix Pharmaceuticals Holding Corp. (TNXP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TNXP research updated on 13F Pro?

TNXP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tonix Pharmaceuticals Holding Corp.(TNXP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1430306 TNXP stock profile & AI dashboard →

13F Pro Quality Score

27.9/100

Rank #2,458 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

98.1/100

Profitability

2.7/100

Balance Sheet

4.4/100

Earnings Quality

30.0/100

Free Cash Flow

2.7/100

Institutional Flow

85.5/100

Revenue Scale

4.4/100

Dilution Risk

5.0/100

TNXP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tonix Pharmaceuticals Holding Corp. (TNXP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNXP at 27.9/100 on a 32-signal composite quality model, placing it at rank #2,458 of 2,879 stocks — the bottom half of the AI-ranked universe. TNXP scores in the top quartile across revenue growth (98.1), institutional flow (85.5). Areas of concern include profitability (2.7) and free cash flow (2.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Tonix Pharmaceuticals Holding Corp. reports quarterly revenue of $6.9M, net income of $-40.2M, free cash flow of $-44.0M. Top institutional holders of TNXP by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. TNXP trades on the Nasdaq exchange and files with the SEC under CIK 1430306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tonix Pharmaceuticals Holding Corp. directly from SEC EDGAR. Tonix Pharmaceuticals Holding Corp.'s 13F Pro composite quality score has ranged between 9 and 28 since 2025, currently 27.9 — an improving long-term trajectory across 11 quarterly and live scoring snapshots.

✦

Fun facts about Tonix Pharmaceuticals Holding Corp.

Quirks, history, and lore behind TNXP — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · focused on developing treatments for central nervous system and other disorders.
2
The Numbers
A micro-cap with minimal revenue and a pipeline-dependent balance sheet — like most clinical-stage biotechs, it spends far more on R&D than it takes in.
3
The History
Founded in the early 2010s and headquartered in New York City, it has pursued an ambitious strategy of repurposing and reformulating known compounds for underserved conditions.
4
The Secret
One of its longest-running development programs targets fibromyalgia — a condition notoriously difficult to treat — using a low-dose cyclobenzaprine formulation called TNX-102 SL.
5
The Lore
The company has also pursued treatments for PTSD and alcohol use disorder, giving it one of the broader CNS pipelines for a company of its tiny size.
6
The Giveaway
Its lead drug Tonmya received FDA approval for fibromyalgia in 2023 — a milestone for this Tonix-branded biotech that had been chasing the indication for years.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.9M

Net Income

Q1 2026

$-40.2M

Free Cash Flow

Q1 2026

$-44.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+29.8% YoY

$13.1MFY 2025

FY21 —FY23 $7.8MFY24 $10.1MFY25 $13.1M

Net Income

+4.6% YoY

$-124.0MFY 2025

FY21 $-92.3MFY23 $-116.7MFY24 $-130.0MFY25 $-124.0M

Operating Income

+8.0% YoY

$-125.7MFY 2025

FY21 $-92.3MFY23 $-118.4MFY24 $-136.7MFY25 $-125.7M

EPS (Diluted)

+91.7% YoY

$-14.57FY 2025

FY21 $-0.00FY23 $-4.18FY24 $-176.60FY25 $-14.57

Total Assets

+70.2% YoY

$277.2MFY 2025

FY21 $240.9MFY23 $154.5MFY24 $162.9MFY25 $277.2M

Total Debt

—FY 2025

FY21 —FY23 $13.3MFY24 $11.5MFY25 —

Op. Cash Flow

-63.9% YoY

$-99.8MFY 2025

FY21 $-75.6MFY23 $-102.0MFY24 $-60.9MFY25 $-99.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$13.1M +29.8%	$10.1M +29.9%	$7.8M	—	—	—
Net Income	$-124.0M +4.6%	$-130.0M -11.5%	$-116.7M -26.4%	$-92.3M -82.9%	$-50.5M -76.3%	$-28.6M
Operating Income	$-125.7M +8.0%	$-136.7M -15.5%	$-118.4M -28.2%	$-92.3M -82.8%	$-50.5M -75.2%	$-28.8M
EPS (Diluted)	$-14.57 +91.7%	$-176.60 -4126.6%	$-4.18 -835560.0%	$-0.00	—	—
Total Assets	$277.2M +70.2%	$162.9M +5.5%	$154.5M -35.9%	$240.9M +145.4%	$98.2M +574.4%	$14.6M
Total Debt	—	$11.5M -14.1%	$13.3M	—	—	—
Operating Cash Flow	$-99.8M -63.9%	$-60.9M +40.3%	$-102.0M -35.0%	$-75.6M -55.6%	$-48.6M -82.0%	$-26.7M

AI Insight: TNXP Financial Trends

Revenue inflecting upward to $7M in Q1 2026, but operating losses and cash burn accelerating sharply despite stable debt.

• Revenue grew 40% from $5M in Q4 2025 to $7M in Q1 2026, first material sequential gain in trailing eight quarters.

• Operating cash burn deteriorated to $42M in Q1 2026 from $40M in Q4 2025, widening net quarterly losses to $40M.

• Equity swung from $42M (Q2 2024) to $227M (Q1 2026), driven by capital raises offsetting cumulative operating losses exceeding $300M.

⚠ Operating cash burn ($42M in Q1 2026) now vastly exceeds revenue ($7M), implying 6+ quarters of runway at current burn rate.

⚠ Operating losses ($42M) widened 12.5% in Q1 2026 despite 40% revenue growth, signaling no gross margin relief or operating leverage yet.

AI Insight: TNXP Ratio Trends

Tonix remains deeply unprofitable with negative returns across all metrics; modest leverage reduction offers minimal relief.

• ROE deteriorated to -70.8% in Q1 2026 from -37.3% in Q1 2025, signaling worsening shareholder value destruction year-over-year.

• D/E ratio declined to 0.05 in Q4 2025 and TTM, down from 0.31 in Q2 2024, indicating reduced financial leverage.

• ROIC swung to -73.2% in Q1 2026 from -33.5% in Q1 2025, reflecting persistent operational losses and capital inefficiency.

⚠ Quarterly volatility in ROE/ROA/ROIC suggests episodic losses or cash burns; no path to profitability evident in recent data.

⚠ Operating and net profit margins unavailable; inability to assess if revenue growth, if any, offsets operating cash drain.

Get alerted when TNXP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tonix Pharmaceuticals Holding Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TNXP

BlackRock, Inc.
$13.3M968,177 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.1M518,650 sh
CITADEL ADVISORS LLC
$6.4M468,712 sh
Jones Hill Capital LP
$6.2M452,116 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.3M313,291 sh
BALYASNY ASSET MANAGEMENT L.P.
$4.3M313,082 sh
UBS Group AG
$3.2M231,678 sh
STATE STREET CORP
$3.2M230,607 sh
MILLENNIUM MANAGEMENT LLC
$3.0M219,673 sh
AQR CAPITAL MANAGEMENT LLC
$2.2M161,208 sh

Fund	Value	Shares
BlackRock, Inc.	$13.3M	968,177
VANGUARD CAPITAL MANAGEMENT LLC	$7.1M	518,650
CITADEL ADVISORS LLC	$6.4M	468,712
Jones Hill Capital LP	$6.2M	452,116
GEODE CAPITAL MANAGEMENT, LLC	$4.3M	313,291
BALYASNY ASSET MANAGEMENT L.P.	$4.3M	313,082
UBS Group AG	$3.2M	231,678
STATE STREET CORP	$3.2M	230,607
MILLENNIUM MANAGEMENT LLC	$3.0M	219,673
AQR CAPITAL MANAGEMENT LLC	$2.2M	161,208

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TNXP on your watchlist

Track score changes the day Tonix Pharmaceuticals Holding Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TNXP a good stock to buy?

13F Pro's AI-powered analysis of Tonix Pharmaceuticals Holding Corp. (TNXP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNXP are available on the TNXP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TNXP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNXP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tonix Pharmaceuticals Holding Corp.'s investment landscape.